Zanaflex Capsule
Product Images NDC 83107-003

This is information about Zanaflex (tizanidine) capsules where each capsule contains 2 mg of tizanidine hydrochloride. The recommended dosage is specified in the prescribing information. The storage temperature range is between 20°C to 25°C (68°F to 77°F). It should be dispensed in containers with child-resistant closure. The manufacturer is Legacy Pharma Inc., located in Grand Cayman, KY1-9012, and the product is made in the Czech Republic. Remember to keep this medication out of reach of children.*

This text provides information about a medication called Zanaflex (tizanidine) in capsule form. Each capsule contains 4 mg tizanidine equivalent to 4.58 mg tizanidine hydrochloride. The recommended dosage details are not available in the text, but it advises referring to the prescribing information. Storage instructions specify keeping the medication at 20°C to 25°C (68°F to 77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F). The text also mentions dispensing the medication in containers with child-resistant closures and emphasizes keeping it out of reach of children. The medication is manufactured for Legacy Pharma Inc. in Czech Republic. The text includes batch and expiration information, as well as a GTIN code. This information is important for healthcare professionals and users to safely use and store the medication.*

This is a description for a medication labeled as Zanaflex (tizanidine), containing 150 capsules with each capsule containing 6 mg of tizanidine. The total equivalent amount of tizanidine hydrochloride is 6.87 mg. The recommended dosage information is available in the Prescribing Information. The medication should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). It comes in containers with child-resistant closures. The manufacturer is Legacy Pharma Inc., located in Georgetown, Grand Cayman, KY1-9012, Made in Czech Republic. The label also includes manufacturing and expiration date information.*

This text suggests an evaluation of the improvement in Ashworth Score over time after the administration of different doses of tizanidine (8 mg and 16 mg). The graph shows the progression of the score in hours post-dose.*

This text presents data related to the improvement in Ashworth Score using Tizanidine at a mean dose of 26.8 mg compared to a placebo. It mentions the endpoints of the study at Week 3 and Week 7, with the last observation carried forward for analysis.*